Latest Headlines

Latest Headlines

Biotech unicorn Stemcentrx is reportedly up for a multibillion-dollar sale

Stemcentrx turned heads last year when it came out of stealth with a $250 million funding round that gave the company a reported valuation of $5 billion. Now the biotech, backed by PayPal founder Peter Thiel, is exploring the idea of selling itself, according to The Wall Street Journal, lining up for what could be a blockbuster deal.

VCA charges ahead with $344M deal for vet hospital chain CAPNA

A couple of weeks ago, VCA said that it would buy an 80% stake in Las Vegas-based veterinary hospital chain Companion Animal Practices North America (CAPNA). Now the company is charging ahead with those plans, signing a definitive agreement to move forward with the deal.

Data collection firm ERT is changing private equity hands

Four years after leaving the Nasdaq to go private, patient data specialist ERT is again being sold as private equity owner Genstar Capital prepares to ship the company over to Nordic Capital for an undisclosed sum.

Medtronic to shutter building at Covidien's Massachusetts HQ following last year's megadeal

Medtronic has said that operational changes would be on the way after sealing its $43 billion tax inversion deal with Covidien last year, and some of those are still trickling in. The company is planning to shut down an office building at Covidien's Massachusetts headquarters as part of its restructuring following the merger.

BD forms $500M JV with private equity firm Apax to house ailing respiratory biz

Becton Dickinson is spinning off its poorly performing Respiratory Solutions business into a joint venture with Apax Partners. The company had previously been expected to sell the respiratory business, which it gained as part of the $12.4 billion acquisition of CareFusion that closed almost one year ago. Apax will be the majority owner in the JV with a 50.1% stake.

Amgen is eyeing heftier deals, but so are its biggest rivals

It's no secret that Amgen is scouting for deals. And now, its CFO says, it's open to potentially larger deals than the ones it's made in the past.

J&J;'s Ethicon to buy NeuWave for soft-tissue microwave ablation for cancer

Johnson & Johnson made big promises to pursue innovative device deals after it did a major restructuring of the business early this year. It's working to make good on that strategy with its latest acquisition of NeuWave Medical, which J&J; noted already has its soft tissue microwave ablation tech in place in more than half of the top cancer centers in the U.S.

Amgen heads back to the M&A; table with plans to stay 'disciplined'

Amgen is returning to the world of transformational dealmaking, executives said, looking to capitalize on a market-wide dip in valuations without overspending on hype.

Zoetis and Merial ink pact to market drugs and vaccines for dairy cattle in India

Zoetis and Sanofi's Merial unit are teaming up to market drugs and vaccines for dairy cattle in India. The deal comes as Merial tries to build up its presence in the companion-animal and food-production markets and Zoetis looks to diversify its portfolio to chart growth.

Heart failure startup Corvia nabs acquisition option deal, to start FDA pivotal trial

Corvia Medical has scooped up a potential buyer with a purchase option deal, but the Massachusetts-based startup is remaining hush-hush on the identity of the strategic partner and the deal terms. The deal likely hinges on the outcome of an upcoming trial for its transcatheter InterAtrial Shunt Device to treat heart failure, or the subsequent FDA approval for which it's expected to provide the basis.